Francois-Clement Bidard
Professor of Medical Oncology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Purpose: In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial ( N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST). Experimental Design: Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC ( N = 159) and NST ( N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype. Results: Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)]. Conclusions: ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.
Year:
2025
Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocrine therapy-based treatment.
Year:
2025
Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no)
Year:
2025
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negative, HER2-positive and triple-negative tumors.
Year:
2025
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no).
Year:
2025
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/hormone receptor-negative tumors. Survival time is given as time since baseline CTC assessment in months. The P-values refers to the global log rank test with 3 degrees of freedom.
Year:
2025
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is given as time since baseline CTC assessment in months. (A, C) cutoff for CTC positivity ≥1 CTC; (B, D) cutoff for CTC positivity ≥5 CTCs. The P-values refer to pairwise comparisons with the log rank test.
Year:
2025
Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time since baseline CTC assessment in months. (A, D) hormone receptor-positive/HER2-negative tumors; (B, E) HER2- positive tumors; (C, F) triple-negative tumors. The P-values refer to pairwise comparisons with the log rank test.
Year:
2025
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according to treatment type.
Year:
2025
Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being a CTC responder are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC responder (yes vs no).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (54)
Anne Vincent‐Salomon
Professor (associate)
Université Paris Dauphine-PSL
Charlotte Proudhon
INSERM scientist, Group leader - Team Circulating EpiMarkers
-
Etienne BRAIN
Institut Curie
Emanuela Romano
PSL Research University
Olivier Lantz
Institut Curie
Ivan Bieche
Université Paris Cité
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
Elisabeth de Vries
Scientific Staff
Universitair Medisch Centrum Utrecht
Joyce O'Shaughnessy
Baylor University Medical Center
Catherine Alix-Panabières
Director/Professor
University Hospital of Montpellier
Paola Gazzaniga
Sapienza University of Rome
Patrick Neven
University Hospitals Leuven
Daniel F. Hayes
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
Michail Ignatiadis
Leader Investigator Initiated Trials
Institut Jules Bordet
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Chloé-Agathe Azencott
Professor
Mines ParisTech
Lisa Anne Carey
Deputy Director for Clinical Science
University of North Carolina at Chapel Hill
Scott A. Laurie
University of Ottawa
Lars Dyrskjøt
Aarhus University Hospital
Christophe Le Tourneau
Head of Early Phase Clinical Trials
Institut Curie
Nadia Harbeck
-
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Jean-Yves Pierga
Head of Department
Institut Curie
Karthik Giridhar
Assistant Professor
Mayo Clinic
Anne Tardivon
PSL Research University
Kelly K Hunt
Chair
The University of Texas MD Anderson Cancer Center
Tanja Fehm
Professor
University Hospital Düsseldorf
Carlos Caldas
Professor
Hebrew University of Jerusalem
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Leon W. M. M. Terstappen
University of Twente
Luis Teixeira
Université Paris Cité
Peter Fasching
-
Swati Kulkarni
Professor of Surgery
Northwestern University
Véronique Dieras
Head Breast Group
-
Elena Garralda
Director
-
Elisabetta Munzone
Director
European Institute of Oncology
Justin Stebbing
Professor
Imperial College London
Evi Lianidou
PROFESSOR
National and Kapodistrian University of Athens
Hervé J. BRISSE
Head of Imaging Departement
Université PSL
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Anthony Gonçalves
Aix-Marseille University
Virginia Kaklamani
Professor
University of Texas Health Science Center at San Antonio
Aditya Bardia
UCLA Health
Maud Kamal
Institut Gustave Roussy
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Miguel Martin
Universidad Complutense de Madrid
Klaus Pantel
-
Manali Bhave
Assistant Professor
Winship Cancer Institute of Emory University
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Caroline Malhaire
Institut Curie
Markus Wallwiener
University Hospital Heidelberg
DANIELE GENERALI
University of Trieste
Rodrigo Toledo
Miguel Servet Researcher (Assistant Professor)
Vall d'Hebron Institute of Oncology
Kostandinos Sideras
Assistant Professor
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.